Compare TLS & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | VYGR |
|---|---|---|
| Founded | 1969 | 2013 |
| Country | United States | United States |
| Employees | N/A | 172 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 226.8M |
| IPO Year | 2020 | 2015 |
| Metric | TLS | VYGR |
|---|---|---|
| Price | $5.18 | $4.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | $7.75 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 1.0M | 433.3K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $144,400,000.00 | $31,316,000.00 |
| Revenue This Year | $52.27 | N/A |
| Revenue Next Year | $20.44 | $71.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.44 | N/A |
| 52 Week Low | $1.83 | $2.65 |
| 52 Week High | $8.36 | $6.27 |
| Indicator | TLS | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 39.52 | 45.47 |
| Support Level | $4.97 | $3.93 |
| Resistance Level | $5.85 | $4.26 |
| Average True Range (ATR) | 0.33 | 0.21 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 15.40 | 21.53 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.